+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)
Immuno-Oncology Market - Global Forecast 2026-2032- Product Image
Immuno-Oncology Market - Global Forecast 2026-2032- Product Image
Sale

Immuno-Oncology Market - Global Forecast 2026-2032

  • Report

  • 188 Pages
  • September 2026
  • Region: Global
  • 360iResearch™
  • ID: 5889363
UP TO OFF until Jan 01st 2027
1h Free Analyst Time
Description Jump to:
1h Free Analyst Time

Speak directly to the analyst to clarify any post sales queries you may have.
The Immuno-Oncology Market is projected to reach USD 44.51 Billion in 2026. It is expected to continue growing at a CAGR of 17.41%, reaching USD 117.00 Billion by 2032.

Immuno-Oncology: Executive Overview of a Transforming Cancer-Treatment Field

Immuno-oncology applies immune-system biology to cancer treatment, prevention, diagnosis, and monitoring. Its central premise is to restore, strengthen, or redirect immune responses against malignant cells. The field includes immune checkpoint inhibition, cellular therapies, cancer vaccines, immune-modulating antibodies, cytokine-based approaches, and combination regimens. Clinical progress has broadened the role of immune-based treatments across several tumor types, while also highlighting challenges involving patient selection, resistance, immune-related toxicity, manufacturing, and equitable access.

From Single-Agent Innovation to Integrated, Biomarker-Guided Care

The landscape is shifting from isolated immunotherapies toward treatment strategies that combine immune activation with surgery, radiotherapy, chemotherapy, targeted therapy, antibody-drug conjugates, and other precision approaches. Biomarkers such as tumor mutational characteristics, immune-cell profiles, antigen expression, and circulating signals are increasingly used to guide treatment decisions, although their predictive reliability varies by cancer type and clinical setting. Research is also moving toward earlier-stage disease, perioperative use, personalized cellular products, and approaches intended to overcome primary and acquired resistance. These changes increase the importance of multidisciplinary care, longitudinal monitoring, and evidence that reflects real-world patient diversity.

Artificial Intelligence Is Accelerating Discovery, Selection, and Monitoring

Artificial intelligence is contributing across the immuno-oncology value chain by supporting biomarker discovery, pathology interpretation, medical-image analysis, clinical-trial matching, pharmacovigilance, and treatment-response assessment. Machine-learning models can integrate genomic, transcriptomic, imaging, and clinical data to identify patterns that may improve patient stratification and reveal mechanisms of resistance. Generative methods may assist with hypothesis generation and documentation, but their outputs require independent validation. Key safeguards include representative training data, transparent performance measures, human oversight, protection of sensitive health information, and prospective evaluation before clinical deployment.

Regional Dynamics Reflect Uneven Innovation, Infrastructure, and Access

North America is characterized by strong translational research capacity, specialized cancer centers, advanced diagnostics, and comparatively broad experience with complex immune-based treatments. Europe combines sophisticated research networks with coordinated regulatory and health-technology-assessment processes, while access and reimbursement can differ across countries. Asia-Pacific is supported by substantial clinical-research activity, growing biologics and cell-therapy capabilities, and varied healthcare systems; Japan, China, South Korea, India, and Australia each present distinct regulatory and delivery environments. Latin America continues to face disparities in diagnostic capacity, specialist availability, and reimbursement, despite expanding oncology expertise. The Middle East is investing in tertiary-care infrastructure and precision medicine, whereas Africa’s progress is shaped by limited oncology capacity, uneven access to diagnostics, workforce constraints, and the need for locally relevant implementation models.

Economic and Political Groupings Shape Collaboration and Readiness

ASEAN countries show varied levels of oncology infrastructure and regulatory maturity, creating opportunities for regional cooperation in trials, procurement, and workforce development. BRICS members span major research, manufacturing, and patient populations but differ substantially in health-system capacity and access pathways. The European Union benefits from shared scientific and regulatory mechanisms, while national reimbursement decisions remain important. G7 countries generally possess advanced research and clinical infrastructure, with continued emphasis on safety, evidence quality, and sustainable healthcare delivery. GCC states are expanding specialized care, genomics, and digital-health capabilities, although reliance on imported expertise and products remains relevant. NATO members represent a diverse set of health systems, and collaboration may support emergency preparedness, supply-chain resilience, and biomedical research coordination.

Country-Level Priorities Range from Research Leadership to Access Expansion

The United States combines extensive clinical research, advanced cancer centers, and broad experience with immunotherapy, while Canada emphasizes coordinated public healthcare and evidence-based access. The United Kingdom, France, Germany, Italy, and Spain possess established oncology networks, but differ in assessment, reimbursement, and regional delivery arrangements. China is strengthening domestic innovation, clinical research, and manufacturing, while Japan and South Korea continue to develop sophisticated oncology and cell-therapy ecosystems. India is expanding research and treatment capacity while confronting affordability and geographic-access challenges. Australia supports high-quality cancer research and specialized care across a geographically dispersed population. Brazil and Mexico are building oncology capabilities amid pronounced public-private differences and regional disparities. Russia maintains specialized scientific and clinical institutions, while access, supply continuity, and international collaboration conditions influence implementation.

Prioritize Evidence Quality, Patient Selection, and Delivery Capability

Industry leaders should build development programs around clinically meaningful outcomes, robust biomarker strategies, and diverse enrollment that reflects routine-care populations. Resistance planning should be embedded early through combination research, serial sampling, and validated response-monitoring methods. Organizations should invest in manufacturing controls, cold-chain and logistics readiness, treatment-center training, and systems for detecting and managing immune-related adverse events. Responsible use of artificial intelligence requires documented validation, cybersecurity, governance, and clinician accountability. Partnerships with health systems, regulators, patient groups, and local research institutions can improve implementation, while access strategies should address diagnostic prerequisites, affordability, geographic reach, and continuity of care.

Methodology: Evidence Synthesis Across Science, Care Delivery, and Policy

This executive summary uses a structured qualitative synthesis of established immuno-oncology concepts, clinical-development patterns, biomarker practices, artificial-intelligence applications, healthcare-system characteristics, and regional policy considerations. Findings are organized across therapeutic innovation, diagnostics, manufacturing, regulation, reimbursement, infrastructure, and patient access. Regional, group, and country observations are presented as contextual comparisons rather than quantitative rankings. The approach prioritizes verifiable scientific and healthcare-system information, distinguishes established applications from emerging opportunities, and avoids unsupported numerical claims. Because conditions evolve rapidly, individual clinical or investment decisions should be checked against current regulatory guidance, peer-reviewed evidence, and local health-system requirements.

Immuno-Oncology’s Next Phase Depends on Translational Rigor and Inclusive Delivery

Immuno-oncology has changed cancer care by making immune biology a central therapeutic focus, but durable benefit remains dependent on appropriate patient selection, effective management of toxicity, resistance mitigation, and reliable delivery. Artificial intelligence may strengthen discovery and personalization when governed with clinical discipline and high-quality data. The field’s progress will increasingly be measured not only by scientific breakthroughs, but also by reproducible outcomes, patient-centered care, manufacturing resilience, and equitable access across health systems. Leaders that connect innovation with implementation, evidence, and responsible governance will be best positioned to advance the next generation of immune-based cancer care.

 

Additional Product Information:

  • Purchase of this report includes 1 year online access with quarterly updates.
  • This report can be updated on request. Please contact our Customer Experience team using the Ask a Question widget on our website.

Table of Contents

1. Preface
1.1. Objectives of the Study
1.2. Market Definition
1.3. Market Segmentation & Coverage
1.4. Years Considered for the Study
1.5. Currency Considered for the Study
1.6. Language Considered for the Study
1.7. Key Stakeholders
2. Research Methodology
2.1. Introduction
2.2. Research Design
2.2.1. Primary Research
2.2.2. Secondary Research
2.3. Research Framework
2.3.1. Qualitative Analysis
2.3.2. Quantitative Analysis
2.4. Market Size Estimation
2.4.1. Top-Down Approach
2.4.2. Bottom-Up Approach
2.5. Data Triangulation
2.6. Research Outcomes
2.7. Research Assumptions
2.8. Research Limitations
3. Executive Summary
3.1. Introduction
3.2. CXO Perspective
3.3. New Revenue Opportunities
3.4. Next-Generation Business Models
3.5. Industry Roadmap
4. Market Overview
4.1. Introduction
4.2. Industry Ecosystem & Value Chain Analysis
4.2.1. Supply-Side Analysis
4.2.2. Demand-Side Analysis
4.2.3. Stakeholder Analysis
4.3. Market Dynamics
4.3.1. Key Drivers
4.3.2. Key Restraints
4.3.3. Key Opportunities
4.3.4. Key Challenges
4.4. Porter’s Five Forces Analysis
4.5. PESTLE Analysis
4.6. Market Outlook
4.6.1. Near-Term Market Outlook (0-2 Years)
4.6.2. Medium-Term Market Outlook (3-5 Years)
4.6.3. Long-Term Market Outlook (5-10 Years)
4.7. Go-to-Market Strategy
5. Market Insights
5.1. Consumer Insights & End-User Perspective
5.2. Consumer Experience Benchmarking
5.3. Opportunity Mapping
5.4. Distribution Channel Analysis
5.5. Pricing Trend Analysis
5.6. Regulatory Compliance & Standards Framework
5.7. ESG & Sustainability Analysis
5.8. Disruption & Risk Scenarios
5.9. Return on Investment & Cost-Benefit Analysis
6. Cumulative Impact of Artificial Intelligence 2026
7. Immuno-Oncology Market, by Therapy Type
7.1. Introduction
7.2. Cancer Vaccines
7.3. Cell Therapy
7.3.1. CAR-T Therapy
7.3.2. NK Cell Therapy
7.3.3. TCR-T Therapy
7.4. Checkpoint Inhibitors
7.4.1. CTLA-4 Inhibitors
7.4.2. PD-1 Inhibitors
7.4.3. PD-L1 Inhibitors
7.5. Cytokines
7.6. Oncolytic Viruses
8. Immuno-Oncology Market, by Indication
8.1. Introduction
8.2. Breast Cancer
8.2.1. Her2-Positive Breast Cancer
8.2.2. Triple-Negative Breast Cancer
8.3. Colorectal Cancer
8.4. Lung Cancer
8.5. Lymphoma
8.6. Melanoma
8.6.1. Cutaneous Melanoma
8.6.2. Uveal Melanoma
9. Immuno-Oncology Market, by Line Of Therapy
9.1. Introduction
9.2. First Line
9.3. Fourth Line
9.4. Second Line
9.5. Third Line
10. Immuno-Oncology Market, by End User
10.1. Introduction
10.2. Academic Institutes
10.3. Cancer Research Institutes
10.4. Clinics
10.5. Hospitals
11. Immuno-Oncology Market, by Region
11.1. Introduction
11.2. Asia-Pacific
11.3. Europe
11.4. North America
11.5. Latin America
11.6. Africa
11.7. Middle East
12. Immuno-Oncology Market, by Group
12.1. Introduction
12.2. NATO
12.3. G7
12.4. BRICS
12.5. European Union
12.6. ASEAN
12.7. GCC
13. Immuno-Oncology Market, by Country
13.1. Introduction
13.2. China
13.3. United States
13.4. Japan
13.5. India
13.6. Germany
13.7. United Kingdom
13.8. Australia
13.9. France
13.10. South Korea
13.11. Canada
13.12. Italy
13.13. Brazil
13.14. Mexico
13.15. Russia
13.16. Spain
14. Competitive Landscape
14.1. Market Share Analysis, 2025
14.2. Market Concentration Analysis, 2025
14.2.1. Concentration Ratio (CR)
14.2.2. Herfindahl Hirschman Index (HHI)
14.3. Recent Developments & Impact Analysis, 2025
14.4. Product Portfolio Analysis, 2025
14.5. Benchmarking Analysis, 2025
15. Company Profiles
15.1. Agenus Inc.
15.2. Allogene Therapeutics, Inc.
15.3. Amgen Inc.
15.4. AstraZeneca PLC
15.5. Autolus Limited
15.6. BeiGene, Ltd.
15.7. BioNTech SE
15.8. Bristol-Myers Squibb Company
15.9. Celgene Corporation
15.10. Eli Lilly and Company
15.11. Gilead Sciences, Inc.
15.12. GlaxoSmithKline plc
15.13. Immutep Ltd.
15.14. Johnson & Johnson
15.15. Juno Therapeutics, Inc.
15.16. Legend Biotech Corporation
15.17. Merck & Co., Inc.
15.18. Moderna, Inc.
15.19. Novartis AG
15.20. Pfizer Inc.
15.21. Regeneron Pharmaceuticals, Inc.
15.22. Roche Holding AG
15.23. Sanofi S.A.
15.24. Takeda Pharmaceutical Company Limited
16. Key Experts
LIST OF FIGURES
FIGURE 1. Global Immuno-Oncology Market, Years Considered for the Study
FIGURE 2. Global Immuno-Oncology Market, Research Design
FIGURE 3. Global Immuno-Oncology Market, Research Framework
FIGURE 4. Global Immuno-Oncology Market, Data Triangulation
FIGURE 5. Global Immuno-Oncology Market Size, 2017-2032 (USD Million)
FIGURE 6. Global Immuno-Oncology Market Size, by Therapy Type, 2025 vs 2032 (%)
FIGURE 7. Global Immuno-Oncology Market Size, by Therapy Type, 2025 vs 2026 vs 2032 (USD Million)
FIGURE 8. Global Immuno-Oncology Market Size, by Indication, 2025 vs 2032 (%)
FIGURE 9. Global Immuno-Oncology Market Size, by Indication, 2025 vs 2026 vs 2032 (USD Million)
FIGURE 10. Global Immuno-Oncology Market Size, by Line Of Therapy, 2025 vs 2032 (%)
FIGURE 11. Global Immuno-Oncology Market Size, by Line Of Therapy, 2025 vs 2026 vs 2032 (USD Million)
FIGURE 12. Global Immuno-Oncology Market Size, by End User, 2025 vs 2032 (%)
FIGURE 13. Global Immuno-Oncology Market Size, by End User, 2025 vs 2026 vs 2032 (USD Million)
FIGURE 14. Global Immuno-Oncology Market Size, by Region, 2025 vs 2032 (%)
FIGURE 15. Global Immuno-Oncology Market Size, by Region, 2025 vs 2026 vs 2032 (USD Million)
FIGURE 16. Global Immuno-Oncology Market Size, by Group, 2025 vs 2026 vs 2032 (USD Million)
FIGURE 17. Global Immuno-Oncology Market Size, by Country, 2025 vs 2032 (%)
FIGURE 18. Global Immuno-Oncology Market Size, by Country, 2025 vs 2026 vs 2032 (USD Million)
FIGURE 19. Global Immuno-Oncology Market Share, by Key Player, 2025
LIST OF TABLES
TABLE 1. Global Immuno-Oncology Market Segmentation & Coverage
TABLE 2. Global Immuno-Oncology Market Size, 2017-2032 (USD Million)
TABLE 3. Global Immuno-Oncology Market Size, by Therapy Type, 2017-2032 (USD Million)
TABLE 4. Global Cancer Vaccines Market Size, by Region, 2017-2032 (USD Million)
TABLE 5. Global Cancer Vaccines Market Size, by Group, 2017-2032 (USD Million)
TABLE 6. Global Cancer Vaccines Market Size, by Country, 2017-2032 (USD Million)
TABLE 7. Global Cell Therapy Market Size, by Region, 2017-2032 (USD Million)
TABLE 8. Global Cell Therapy Market Size, by Group, 2017-2032 (USD Million)
TABLE 9. Global Cell Therapy Market Size, by Country, 2017-2032 (USD Million)
TABLE 10. Global CAR-T Therapy Market Size, by Region, 2017-2032 (USD Million)
TABLE 11. Global CAR-T Therapy Market Size, by Group, 2017-2032 (USD Million)
TABLE 12. Global CAR-T Therapy Market Size, by Country, 2017-2032 (USD Million)
TABLE 13. Global NK Cell Therapy Market Size, by Region, 2017-2032 (USD Million)
TABLE 14. Global NK Cell Therapy Market Size, by Group, 2017-2032 (USD Million)
TABLE 15. Global NK Cell Therapy Market Size, by Country, 2017-2032 (USD Million)
TABLE 16. Global TCR-T Therapy Market Size, by Region, 2017-2032 (USD Million)
TABLE 17. Global TCR-T Therapy Market Size, by Group, 2017-2032 (USD Million)
TABLE 18. Global TCR-T Therapy Market Size, by Country, 2017-2032 (USD Million)
TABLE 19. Global Checkpoint Inhibitors Market Size, by Region, 2017-2032 (USD Million)
TABLE 20. Global Checkpoint Inhibitors Market Size, by Group, 2017-2032 (USD Million)
TABLE 21. Global Checkpoint Inhibitors Market Size, by Country, 2017-2032 (USD Million)
TABLE 22. Global CTLA-4 Inhibitors Market Size, by Region, 2017-2032 (USD Million)
TABLE 23. Global CTLA-4 Inhibitors Market Size, by Group, 2017-2032 (USD Million)
TABLE 24. Global CTLA-4 Inhibitors Market Size, by Country, 2017-2032 (USD Million)
TABLE 25. Global PD-1 Inhibitors Market Size, by Region, 2017-2032 (USD Million)
TABLE 26. Global PD-1 Inhibitors Market Size, by Group, 2017-2032 (USD Million)
TABLE 27. Global PD-1 Inhibitors Market Size, by Country, 2017-2032 (USD Million)
TABLE 28. Global PD-L1 Inhibitors Market Size, by Region, 2017-2032 (USD Million)
TABLE 29. Global PD-L1 Inhibitors Market Size, by Group, 2017-2032 (USD Million)
TABLE 30. Global PD-L1 Inhibitors Market Size, by Country, 2017-2032 (USD Million)
TABLE 31. Global Cytokines Market Size, by Region, 2017-2032 (USD Million)
TABLE 32. Global Cytokines Market Size, by Group, 2017-2032 (USD Million)
TABLE 33. Global Cytokines Market Size, by Country, 2017-2032 (USD Million)
TABLE 34. Global Oncolytic Viruses Market Size, by Region, 2017-2032 (USD Million)
TABLE 35. Global Oncolytic Viruses Market Size, by Group, 2017-2032 (USD Million)
TABLE 36. Global Oncolytic Viruses Market Size, by Country, 2017-2032 (USD Million)
TABLE 37. Global Immuno-Oncology Market Size, by Indication, 2017-2032 (USD Million)
TABLE 38. Global Breast Cancer Market Size, by Region, 2017-2032 (USD Million)
TABLE 39. Global Breast Cancer Market Size, by Group, 2017-2032 (USD Million)
TABLE 40. Global Breast Cancer Market Size, by Country, 2017-2032 (USD Million)
TABLE 41. Global Her2-Positive Breast Cancer Market Size, by Region, 2017-2032 (USD Million)
TABLE 42. Global Her2-Positive Breast Cancer Market Size, by Group, 2017-2032 (USD Million)
TABLE 43. Global Her2-Positive Breast Cancer Market Size, by Country, 2017-2032 (USD Million)
TABLE 44. Global Triple-Negative Breast Cancer Market Size, by Region, 2017-2032 (USD Million)
TABLE 45. Global Triple-Negative Breast Cancer Market Size, by Group, 2017-2032 (USD Million)
TABLE 46. Global Triple-Negative Breast Cancer Market Size, by Country, 2017-2032 (USD Million)
TABLE 47. Global Colorectal Cancer Market Size, by Region, 2017-2032 (USD Million)
TABLE 48. Global Colorectal Cancer Market Size, by Group, 2017-2032 (USD Million)
TABLE 49. Global Colorectal Cancer Market Size, by Country, 2017-2032 (USD Million)
TABLE 50. Global Lung Cancer Market Size, by Region, 2017-2032 (USD Million)
TABLE 51. Global Lung Cancer Market Size, by Group, 2017-2032 (USD Million)
TABLE 52. Global Lung Cancer Market Size, by Country, 2017-2032 (USD Million)
TABLE 53. Global Lymphoma Market Size, by Region, 2017-2032 (USD Million)
TABLE 54. Global Lymphoma Market Size, by Group, 2017-2032 (USD Million)
TABLE 55. Global Lymphoma Market Size, by Country, 2017-2032 (USD Million)
TABLE 56. Global Melanoma Market Size, by Region, 2017-2032 (USD Million)
TABLE 57. Global Melanoma Market Size, by Group, 2017-2032 (USD Million)
TABLE 58. Global Melanoma Market Size, by Country, 2017-2032 (USD Million)
TABLE 59. Global Cutaneous Melanoma Market Size, by Region, 2017-2032 (USD Million)
TABLE 60. Global Cutaneous Melanoma Market Size, by Group, 2017-2032 (USD Million)
TABLE 61. Global Cutaneous Melanoma Market Size, by Country, 2017-2032 (USD Million)
TABLE 62. Global Uveal Melanoma Market Size, by Region, 2017-2032 (USD Million)
TABLE 63. Global Uveal Melanoma Market Size, by Group, 2017-2032 (USD Million)
TABLE 64. Global Uveal Melanoma Market Size, by Country, 2017-2032 (USD Million)
TABLE 65. Global Immuno-Oncology Market Size, by Line Of Therapy, 2017-2032 (USD Million)
TABLE 66. Global First Line Market Size, by Region, 2017-2032 (USD Million)
TABLE 67. Global First Line Market Size, by Group, 2017-2032 (USD Million)
TABLE 68. Global First Line Market Size, by Country, 2017-2032 (USD Million)
TABLE 69. Global Fourth Line Market Size, by Region, 2017-2032 (USD Million)
TABLE 70. Global Fourth Line Market Size, by Group, 2017-2032 (USD Million)
TABLE 71. Global Fourth Line Market Size, by Country, 2017-2032 (USD Million)
TABLE 72. Global Second Line Market Size, by Region, 2017-2032 (USD Million)
TABLE 73. Global Second Line Market Size, by Group, 2017-2032 (USD Million)
TABLE 74. Global Second Line Market Size, by Country, 2017-2032 (USD Million)
TABLE 75. Global Third Line Market Size, by Region, 2017-2032 (USD Million)
TABLE 76. Global Third Line Market Size, by Group, 2017-2032 (USD Million)
TABLE 77. Global Third Line Market Size, by Country, 2017-2032 (USD Million)
TABLE 78. Global Immuno-Oncology Market Size, by End User, 2017-2032 (USD Million)
TABLE 79. Global Academic Institutes Market Size, by Region, 2017-2032 (USD Million)
TABLE 80. Global Academic Institutes Market Size, by Group, 2017-2032 (USD Million)
TABLE 81. Global Academic Institutes Market Size, by Country, 2017-2032 (USD Million)
TABLE 82. Global Cancer Research Institutes Market Size, by Region, 2017-2032 (USD Million)
TABLE 83. Global Cancer Research Institutes Market Size, by Group, 2017-2032 (USD Million)
TABLE 84. Global Cancer Research Institutes Market Size, by Country, 2017-2032 (USD Million)
TABLE 85. Global Clinics Market Size, by Region, 2017-2032 (USD Million)
TABLE 86. Global Clinics Market Size, by Group, 2017-2032 (USD Million)
TABLE 87. Global Clinics Market Size, by Country, 2017-2032 (USD Million)
TABLE 88. Global Hospitals Market Size, by Region, 2017-2032 (USD Million)
TABLE 89. Global Hospitals Market Size, by Group, 2017-2032 (USD Million)
TABLE 90. Global Hospitals Market Size, by Country, 2017-2032 (USD Million)
TABLE 91. Global Immuno-Oncology Market Size, by Region, 2017-2032 (USD Million)
TABLE 92. Asia-Pacific Immuno-Oncology Market Size, by Region, 2017-2032 (USD Million)
TABLE 93. Asia-Pacific Immuno-Oncology Market Size, by Therapy Type, 2017-2032 (USD Million)
TABLE 94. Asia-Pacific Immuno-Oncology Market Size, by Cell Therapy, 2017-2032 (USD Million)
TABLE 95. Asia-Pacific Immuno-Oncology Market Size, by Checkpoint Inhibitors, 2017-2032 (USD Million)
TABLE 96. Asia-Pacific Immuno-Oncology Market Size, by Indication, 2017-2032 (USD Million)
TABLE 97. Asia-Pacific Immuno-Oncology Market Size, by Breast Cancer, 2017-2032 (USD Million)
TABLE 98. Asia-Pacific Immuno-Oncology Market Size, by Melanoma, 2017-2032 (USD Million)
TABLE 99. Asia-Pacific Immuno-Oncology Market Size, by Line Of Therapy, 2017-2032 (USD Million)
TABLE 100. Asia-Pacific Immuno-Oncology Market Size, by End User, 2017-2032 (USD Million)
TABLE 101. Europe Immuno-Oncology Market Size, by Region, 2017-2032 (USD Million)
TABLE 102. Europe Immuno-Oncology Market Size, by Therapy Type, 2017-2032 (USD Million)
TABLE 103. Europe Immuno-Oncology Market Size, by Cell Therapy, 2017-2032 (USD Million)
TABLE 104. Europe Immuno-Oncology Market Size, by Checkpoint Inhibitors, 2017-2032 (USD Million)
TABLE 105. Europe Immuno-Oncology Market Size, by Indication, 2017-2032 (USD Million)
TABLE 106. Europe Immuno-Oncology Market Size, by Breast Cancer, 2017-2032 (USD Million)
TABLE 107. Europe Immuno-Oncology Market Size, by Melanoma, 2017-2032 (USD Million)
TABLE 108. Europe Immuno-Oncology Market Size, by Line Of Therapy, 2017-2032 (USD Million)
TABLE 109. Europe Immuno-Oncology Market Size, by End User, 2017-2032 (USD Million)
TABLE 110. North America Immuno-Oncology Market Size, by Region, 2017-2032 (USD Million)
TABLE 111. North America Immuno-Oncology Market Size, by Therapy Type, 2017-2032 (USD Million)
TABLE 112. North America Immuno-Oncology Market Size, by Cell Therapy, 2017-2032 (USD Million)
TABLE 113. North America Immuno-Oncology Market Size, by Checkpoint Inhibitors, 2017-2032 (USD Million)
TABLE 114. North America Immuno-Oncology Market Size, by Indication, 2017-2032 (USD Million)
TABLE 115. North America Immuno-Oncology Market Size, by Breast Cancer, 2017-2032 (USD Million)
TABLE 116. North America Immuno-Oncology Market Size, by Melanoma, 2017-2032 (USD Million)
TABLE 117. North America Immuno-Oncology Market Size, by Line Of Therapy, 2017-2032 (USD Million)
TABLE 118. North America Immuno-Oncology Market Size, by End User, 2017-2032 (USD Million)
TABLE 119. Latin America Immuno-Oncology Market Size, by Region, 2017-2032 (USD Million)
TABLE 120. Latin America Immuno-Oncology Market Size, by Therapy Type, 2017-2032 (USD Million)
TABLE 121. Latin America Immuno-Oncology Market Size, by Cell Therapy, 2017-2032 (USD Million)
TABLE 122. Latin America Immuno-Oncology Market Size, by Checkpoint Inhibitors, 2017-2032 (USD Million)
TABLE 123. Latin America Immuno-Oncology Market Size, by Indication, 2017-2032 (USD Million)
TABLE 124. Latin America Immuno-Oncology Market Size, by Breast Cancer, 2017-2032 (USD Million)
TABLE 125. Latin America Immuno-Oncology Market Size, by Melanoma, 2017-2032 (USD Million)
TABLE 126. Latin America Immuno-Oncology Market Size, by Line Of Therapy, 2017-2032 (USD Million)
TABLE 127. Latin America Immuno-Oncology Market Size, by End User, 2017-2032 (USD Million)
TABLE 128. Africa Immuno-Oncology Market Size, by Region, 2017-2032 (USD Million)
TABLE 129. Africa Immuno-Oncology Market Size, by Therapy Type, 2017-2032 (USD Million)
TABLE 130. Africa Immuno-Oncology Market Size, by Cell Therapy, 2017-2032 (USD Million)
TABLE 131. Africa Immuno-Oncology Market Size, by Checkpoint Inhibitors, 2017-2032 (USD Million)
TABLE 132. Africa Immuno-Oncology Market Size, by Indication, 2017-2032 (USD Million)
TABLE 133. Africa Immuno-Oncology Market Size, by Breast Cancer, 2017-2032 (USD Million)
TABLE 134. Africa Immuno-Oncology Market Size, by Melanoma, 2017-2032 (USD Million)
TABLE 135. Africa Immuno-Oncology Market Size, by Line Of Therapy, 2017-2032 (USD Million)
TABLE 136. Africa Immuno-Oncology Market Size, by End User, 2017-2032 (USD Million)
TABLE 137. Middle East Immuno-Oncology Market Size, by Region, 2017-2032 (USD Million)
TABLE 138. Middle East Immuno-Oncology Market Size, by Therapy Type, 2017-2032 (USD Million)
TABLE 139. Middle East Immuno-Oncology Market Size, by Cell Therapy, 2017-2032 (USD Million)
TABLE 140. Middle East Immuno-Oncology Market Size, by Checkpoint Inhibitors, 2017-2032 (USD Million)
TABLE 141. Middle East Immuno-Oncology Market Size, by Indication, 2017-2032 (USD Million)
TABLE 142. Middle East Immuno-Oncology Market Size, by Breast Cancer, 2017-2032 (USD Million)
TABLE 143. Middle East Immuno-Oncology Market Size, by Melanoma, 2017-2032 (USD Million)
TABLE 144. Middle East Immuno-Oncology Market Size, by Line Of Therapy, 2017-2032 (USD Million)
TABLE 145. Middle East Immuno-Oncology Market Size, by End User, 2017-2032 (USD Million)
TABLE 146. Global Immuno-Oncology Market Size, by Group, 2017-2032 (USD Million)
TABLE 147. NATO Immuno-Oncology Market Size, by Group, 2017-2032 (USD Million)
TABLE 148. NATO Immuno-Oncology Market Size, by Therapy Type, 2017-2032 (USD Million)
TABLE 149. NATO Immuno-Oncology Market Size, by Cell Therapy, 2017-2032 (USD Million)
TABLE 150. NATO Immuno-Oncology Market Size, by Checkpoint Inhibitors, 2017-2032 (USD Million)
TABLE 151. NATO Immuno-Oncology Market Size, by Indication, 2017-2032 (USD Million)
TABLE 152. NATO Immuno-Oncology Market Size, by Breast Cancer, 2017-2032 (USD Million)
TABLE 153. NATO Immuno-Oncology Market Size, by Melanoma, 2017-2032 (USD Million)
TABLE 154. NATO Immuno-Oncology Market Size, by Line Of Therapy, 2017-2032 (USD Million)
TABLE 155. NATO Immuno-Oncology Market Size, by End User, 2017-2032 (USD Million)
TABLE 156. G7 Immuno-Oncology Market Size, by Group, 2017-2032 (USD Million)
TABLE 157. G7 Immuno-Oncology Market Size, by Therapy Type, 2017-2032 (USD Million)
TABLE 158. G7 Immuno-Oncology Market Size, by Cell Therapy, 2017-2032 (USD Million)
TABLE 159. G7 Immuno-Oncology Market Size, by Checkpoint Inhibitors, 2017-2032 (USD Million)
TABLE 160. G7 Immuno-Oncology Market Size, by Indication, 2017-2032 (USD Million)
TABLE 161. G7 Immuno-Oncology Market Size, by Breast Cancer, 2017-2032 (USD Million)
TABLE 162. G7 Immuno-Oncology Market Size, by Melanoma, 2017-2032 (USD Million)
TABLE 163. G7 Immuno-Oncology Market Size, by Line Of Therapy, 2017-2032 (USD Million)
TABLE 164. G7 Immuno-Oncology Market Size, by End User, 2017-2032 (USD Million)
TABLE 165. BRICS Immuno-Oncology Market Size, by Group, 2017-2032 (USD Million)
TABLE 166. BRICS Immuno-Oncology Market Size, by Therapy Type, 2017-2032 (USD Million)
TABLE 167. BRICS Immuno-Oncology Market Size, by Cell Therapy, 2017-2032 (USD Million)
TABLE 168. BRICS Immuno-Oncology Market Size, by Checkpoint Inhibitors, 2017-2032 (USD Million)
TABLE 169. BRICS Immuno-Oncology Market Size, by Indication, 2017-2032 (USD Million)
TABLE 170. BRICS Immuno-Oncology Market Size, by Breast Cancer, 2017-2032 (USD Million)
TABLE 171. BRICS Immuno-Oncology Market Size, by Melanoma, 2017-2032 (USD Million)
TABLE 172. BRICS Immuno-Oncology Market Size, by Line Of Therapy, 2017-2032 (USD Million)
TABLE 173. BRICS Immuno-Oncology Market Size, by End User, 2017-2032 (USD Million)
TABLE 174. European Union Immuno-Oncology Market Size, by Group, 2017-2032 (USD Million)
TABLE 175. European Union Immuno-Oncology Market Size, by Therapy Type, 2017-2032 (USD Million)
TABLE 176. European Union Immuno-Oncology Market Size, by Cell Therapy, 2017-2032 (USD Million)
TABLE 177. European Union Immuno-Oncology Market Size, by Checkpoint Inhibitors, 2017-2032 (USD Million)
TABLE 178. European Union Immuno-Oncology Market Size, by Indication, 2017-2032 (USD Million)
TABLE 179. European Union Immuno-Oncology Market Size, by Breast Cancer, 2017-2032 (USD Million)
TABLE 180. European Union Immuno-Oncology Market Size, by Melanoma, 2017-2032 (USD Million)
TABLE 181. European Union Immuno-Oncology Market Size, by Line Of Therapy, 2017-2032 (USD Million)
TABLE 182. European Union Immuno-Oncology Market Size, by End User, 2017-2032 (USD Million)
TABLE 183. ASEAN Immuno-Oncology Market Size, by Group, 2017-2032 (USD Million)
TABLE 184. ASEAN Immuno-Oncology Market Size, by Therapy Type, 2017-2032 (USD Million)
TABLE 185. ASEAN Immuno-Oncology Market Size, by Cell Therapy, 2017-2032 (USD Million)
TABLE 186. ASEAN Immuno-Oncology Market Size, by Checkpoint Inhibitors, 2017-2032 (USD Million)
TABLE 187. ASEAN Immuno-Oncology Market Size, by Indication, 2017-2032 (USD Million)
TABLE 188. ASEAN Immuno-Oncology Market Size, by Breast Cancer, 2017-2032 (USD Million)
TABLE 189. ASEAN Immuno-Oncology Market Size, by Melanoma, 2017-2032 (USD Million)
TABLE 190. ASEAN Immuno-Oncology Market Size, by Line Of Therapy, 2017-2032 (USD Million)
TABLE 191. ASEAN Immuno-Oncology Market Size, by End User, 2017-2032 (USD Million)
TABLE 192. GCC Immuno-Oncology Market Size, by Group, 2017-2032 (USD Million)
TABLE 193. GCC Immuno-Oncology Market Size, by Therapy Type, 2017-2032 (USD Million)
TABLE 194. GCC Immuno-Oncology Market Size, by Cell Therapy, 2017-2032 (USD Million)
TABLE 195. GCC Immuno-Oncology Market Size, by Checkpoint Inhibitors, 2017-2032 (USD Million)
TABLE 196. GCC Immuno-Oncology Market Size, by Indication, 2017-2032 (USD Million)
TABLE 197. GCC Immuno-Oncology Market Size, by Breast Cancer, 2017-2032 (USD Million)
TABLE 198. GCC Immuno-Oncology Market Size, by Melanoma, 2017-2032 (USD Million)
TABLE 199. GCC Immuno-Oncology Market Size, by Line Of Therapy, 2017-2032 (USD Million)
TABLE 200. GCC Immuno-Oncology Market Size, by End User, 2017-2032 (USD Million)
TABLE 201. Global Immuno-Oncology Market Size, by Country, 2017-2032 (USD Million)
TABLE 202. China Immuno-Oncology Market Size, 2017-2032 (USD Million)
TABLE 203. China Immuno-Oncology Market Size, by Therapy Type, 2017-2032 (USD Million)
TABLE 204. China Immuno-Oncology Market Size, by Cell Therapy, 2017-2032 (USD Million)
TABLE 205. China Immuno-Oncology Market Size, by Checkpoint Inhibitors, 2017-2032 (USD Million)
TABLE 206. China Immuno-Oncology Market Size, by Indication, 2017-2032 (USD Million)
TABLE 207. China Immuno-Oncology Market Size, by Breast Cancer, 2017-2032 (USD Million)
TABLE 208. China Immuno-Oncology Market Size, by Melanoma, 2017-2032 (USD Million)
TABLE 209. China Immuno-Oncology Market Size, by Line Of Therapy, 2017-2032 (USD Million)
TABLE 210. China Immuno-Oncology Market Size, by End User, 2017-2032 (USD Million)
TABLE 211. United States Immuno-Oncology Market Size, 2017-2032 (USD Million)
TABLE 212. United States Immuno-Oncology Market Size, by Therapy Type, 2017-2032 (USD Million)
TABLE 213. United States Immuno-Oncology Market Size, by Cell Therapy, 2017-2032 (USD Million)
TABLE 214. United States Immuno-Oncology Market Size, by Checkpoint Inhibitors, 2017-2032 (USD Million)
TABLE 215. United States Immuno-Oncology Market Size, by Indication, 2017-2032 (USD Million)
TABLE 216. United States Immuno-Oncology Market Size, by Breast Cancer, 2017-2032 (USD Million)
TABLE 217. United States Immuno-Oncology Market Size, by Melanoma, 2017-2032 (USD Million)
TABLE 218. United States Immuno-Oncology Market Size, by Line Of Therapy, 2017-2032 (USD Million)
TABLE 219. United States Immuno-Oncology Market Size, by End User, 2017-2032 (USD Million)
TABLE 220. Japan Immuno-Oncology Market Size, 2017-2032 (USD Million)
TABLE 221. Japan Immuno-Oncology Market Size, by Therapy Type, 2017-2032 (USD Million)
TABLE 222. Japan Immuno-Oncology Market Size, by Cell Therapy, 2017-2032 (USD Million)
TABLE 223. Japan Immuno-Oncology Market Size, by Checkpoint Inhibitors, 2017-2032 (USD Million)
TABLE 224. Japan Immuno-Oncology Market Size, by Indication, 2017-2032 (USD Million)
TABLE 225. Japan Immuno-Oncology Market Size, by Breast Cancer, 2017-2032 (USD Million)
TABLE 226. Japan Immuno-Oncology Market Size, by Melanoma, 2017-2032 (USD Million)
TABLE 227. Japan Immuno-Oncology Market Size, by Line Of Therapy, 2017-2032 (USD Million)
TABLE 228. Japan Immuno-Oncology Market Size, by End User, 2017-2032 (USD Million)
TABLE 229. India Immuno-Oncology Market Size, 2017-2032 (USD Million)
TABLE 230. India Immuno-Oncology Market Size, by Therapy Type, 2017-2032 (USD Million)
TABLE 231. India Immuno-Oncology Market Size, by Cell Therapy, 2017-2032 (USD Million)
TABLE 232. India Immuno-Oncology Market Size, by Checkpoint Inhibitors, 2017-2032 (USD Million)
TABLE 233. India Immuno-Oncology Market Size, by Indication, 2017-2032 (USD Million)
TABLE 234. India Immuno-Oncology Market Size, by Breast Cancer, 2017-2032 (USD Million)
TABLE 235. India Immuno-Oncology Market Size, by Melanoma, 2017-2032 (USD Million)
TABLE 236. India Immuno-Oncology Market Size, by Line Of Therapy, 2017-2032 (USD Million)
TABLE 237. India Immuno-Oncology Market Size, by End User, 2017-2032 (USD Million)
TABLE 238. Germany Immuno-Oncology Market Size, 2017-2032 (USD Million)
TABLE 239. Germany Immuno-Oncology Market Size, by Therapy Type, 2017-2032 (USD Million)
TABLE 240. Germany Immuno-Oncology Market Size, by Cell Therapy, 2017-2032 (USD Million)
TABLE 241. Germany Immuno-Oncology Market Size, by Checkpoint Inhibitors, 2017-2032 (USD Million)
TABLE 242. Germany Immuno-Oncology Market Size, by Indication, 2017-2032 (USD Million)
TABLE 243. Germany Immuno-Oncology Market Size, by Breast Cancer, 2017-2032 (USD Million)
TABLE 244. Germany Immuno-Oncology Market Size, by Melanoma, 2017-2032 (USD Million)
TABLE 245. Germany Immuno-Oncology Market Size, by Line Of Therapy, 2017-2032 (USD Million)
TABLE 246. Germany Immuno-Oncology Market Size, by End User, 2017-2032 (USD Million)
TABLE 247. United Kingdom Immuno-Oncology Market Size, 2017-2032 (USD Million)
TABLE 248. United Kingdom Immuno-Oncology Market Size, by Therapy Type, 2017-2032 (USD Million)
TABLE 249. United Kingdom Immuno-Oncology Market Size, by Cell Therapy, 2017-2032 (USD Million)
TABLE 250. United Kingdom Immuno-Oncology Market Size, by Checkpoint Inhibitors, 2017-2032 (USD Million)
TABLE 251. United Kingdom Immuno-Oncology Market Size, by Indication, 2017-2032 (USD Million)
TABLE 252. United Kingdom Immuno-Oncology Market Size, by Breast Cancer, 2017-2032 (USD Million)
TABLE 253. United Kingdom Immuno-Oncology Market Size, by Melanoma, 2017-2032 (USD Million)
TABLE 254. United Kingdom Immuno-Oncology Market Size, by Line Of Therapy, 2017-2032 (USD Million)
TABLE 255. United Kingdom Immuno-Oncology Market Size, by End User, 2017-2032 (USD Million)
TABLE 256. Australia Immuno-Oncology Market Size, 2017-2032 (USD Million)
TABLE 257. Australia Immuno-Oncology Market Size, by Therapy Type, 2017-2032 (USD Million)
TABLE 258. Australia Immuno-Oncology Market Size, by Cell Therapy, 2017-2032 (USD Million)
TABLE 259. Australia Immuno-Oncology Market Size, by Checkpoint Inhibitors, 2017-2032 (USD Million)
TABLE 260. Australia Immuno-Oncology Market Size, by Indication, 2017-2032 (USD Million)
TABLE 261. Australia Immuno-Oncology Market Size, by Breast Cancer, 2017-2032 (USD Million)
TABLE 262. Australia Immuno-Oncology Market Size, by Melanoma, 2017-2032 (USD Million)
TABLE 263. Australia Immuno-Oncology Market Size, by Line Of Therapy, 2017-2032 (USD Million)
TABLE 264. Australia Immuno-Oncology Market Size, by End User, 2017-2032 (USD Million)
TABLE 265. France Immuno-Oncology Market Size, 2017-2032 (USD Million)
TABLE 266. France Immuno-Oncology Market Size, by Therapy Type, 2017-2032 (USD Million)
TABLE 267. France Immuno-Oncology Market Size, by Cell Therapy, 2017-2032 (USD Million)
TABLE 268. France Immuno-Oncology Market Size, by Checkpoint Inhibitors, 2017-2032 (USD Million)
TABLE 269. France Immuno-Oncology Market Size, by Indication, 2017-2032 (USD Million)
TABLE 270. France Immuno-Oncology Market Size, by Breast Cancer, 2017-2032 (USD Million)
TABLE 271. France Immuno-Oncology Market Size, by Melanoma, 2017-2032 (USD Million)
TABLE 272. France Immuno-Oncology Market Size, by Line Of Therapy, 2017-2032 (USD Million)
TABLE 273. France Immuno-Oncology Market Size, by End User, 2017-2032 (USD Million)
TABLE 274. South Korea Immuno-Oncology Market Size, 2017-2032 (USD Million)
TABLE 275. South Korea Immuno-Oncology Market Size, by Therapy Type, 2017-2032 (USD Million)
TABLE 276. South Korea Immuno-Oncology Market Size, by Cell Therapy, 2017-2032 (USD Million)
TABLE 277. South Korea Immuno-Oncology Market Size, by Checkpoint Inhibitors, 2017-2032 (USD Million)
TABLE 278. South Korea Immuno-Oncology Market Size, by Indication, 2017-2032 (USD Million)
TABLE 279. South Korea Immuno-Oncology Market Size, by Breast Cancer, 2017-2032 (USD Million)
TABLE 280. South Korea Immuno-Oncology Market Size, by Melanoma, 2017-2032 (USD Million)
TABLE 281. South Korea Immuno-Oncology Market Size, by Line Of Therapy, 2017-2032 (USD Million)
TABLE 282. South Korea Immuno-Oncology Market Size, by End User, 2017-2032 (USD Million)
TABLE 283. Canada Immuno-Oncology Market Size, 2017-2032 (USD Million)
TABLE 284. Canada Immuno-Oncology Market Size, by Therapy Type, 2017-2032 (USD Million)
TABLE 285. Canada Immuno-Oncology Market Size, by Cell Therapy, 2017-2032 (USD Million)
TABLE 286. Canada Immuno-Oncology Market Size, by Checkpoint Inhibitors, 2017-2032 (USD Million)
TABLE 287. Canada Immuno-Oncology Market Size, by Indication, 2017-2032 (USD Million)
TABLE 288. Canada Immuno-Oncology Market Size, by Breast Cancer, 2017-2032 (USD Million)
TABLE 289. Canada Immuno-Oncology Market Size, by Melanoma, 2017-2032 (USD Million)
TABLE 290. Canada Immuno-Oncology Market Size, by Line Of Therapy, 2017-2032 (USD Million)
TABLE 291. Canada Immuno-Oncology Market Size, by End User, 2017-2032 (USD Million)
TABLE 292. Italy Immuno-Oncology Market Size, 2017-2032 (USD Million)
TABLE 293. Italy Immuno-Oncology Market Size, by Therapy Type, 2017-2032 (USD Million)
TABLE 294. Italy Immuno-Oncology Market Size, by Cell Therapy, 2017-2032 (USD Million)
TABLE 295. Italy Immuno-Oncology Market Size, by Checkpoint Inhibitors, 2017-2032 (USD Million)
TABLE 296. Italy Immuno-Oncology Market Size, by Indication, 2017-2032 (USD Million)
TABLE 297. Italy Immuno-Oncology Market Size, by Breast Cancer, 2017-2032 (USD Million)
TABLE 298. Italy Immuno-Oncology Market Size, by Melanoma, 2017-2032 (USD Million)
TABLE 299. Italy Immuno-Oncology Market Size, by Line Of Therapy, 2017-2032 (USD Million)
TABLE 300. Italy Immuno-Oncology Market Size, by End User, 2017-2032 (USD Million)
TABLE 301. Brazil Immuno-Oncology Market Size, 2017-2032 (USD Million)
TABLE 302. Brazil Immuno-Oncology Market Size, by Therapy Type, 2017-2032 (USD Million)
TABLE 303. Brazil Immuno-Oncology Market Size, by Cell Therapy, 2017-2032 (USD Million)
TABLE 304. Brazil Immuno-Oncology Market Size, by Checkpoint Inhibitors, 2017-2032 (USD Million)
TABLE 305. Brazil Immuno-Oncology Market Size, by Indication, 2017-2032 (USD Million)
TABLE 306. Brazil Immuno-Oncology Market Size, by Breast Cancer, 2017-2032 (USD Million)
TABLE 307. Brazil Immuno-Oncology Market Size, by Melanoma, 2017-2032 (USD Million)
TABLE 308. Brazil Immuno-Oncology Market Size, by Line Of Therapy, 2017-2032 (USD Million)
TABLE 309. Brazil Immuno-Oncology Market Size, by End User, 2017-2032 (USD Million)
TABLE 310. Mexico Immuno-Oncology Market Size, 2017-2032 (USD Million)
TABLE 311. Mexico Immuno-Oncology Market Size, by Therapy Type, 2017-2032 (USD Million)
TABLE 312. Mexico Immuno-Oncology Market Size, by Cell Therapy, 2017-2032 (USD Million)
TABLE 313. Mexico Immuno-Oncology Market Size, by Checkpoint Inhibitors, 2017-2032 (USD Million)
TABLE 314. Mexico Immuno-Oncology Market Size, by Indication, 2017-2032 (USD Million)
TABLE 315. Mexico Immuno-Oncology Market Size, by Breast Cancer, 2017-2032 (USD Million)
TABLE 316. Mexico Immuno-Oncology Market Size, by Melanoma, 2017-2032 (USD Million)
TABLE 317. Mexico Immuno-Oncology Market Size, by Line Of Therapy, 2017-2032 (USD Million)
TABLE 318. Mexico Immuno-Oncology Market Size, by End User, 2017-2032 (USD Million)
TABLE 319. Russia Immuno-Oncology Market Size, 2017-2032 (USD Million)
TABLE 320. Russia Immuno-Oncology Market Size, by Therapy Type, 2017-2032 (USD Million)
TABLE 321. Russia Immuno-Oncology Market Size, by Cell Therapy, 2017-2032 (USD Million)
TABLE 322. Russia Immuno-Oncology Market Size, by Checkpoint Inhibitors, 2017-2032 (USD Million)
TABLE 323. Russia Immuno-Oncology Market Size, by Indication, 2017-2032 (USD Million)
TABLE 324. Russia Immuno-Oncology Market Size, by Breast Cancer, 2017-2032 (USD Million)
TABLE 325. Russia Immuno-Oncology Market Size, by Melanoma, 2017-2032 (USD Million)
TABLE 326. Russia Immuno-Oncology Market Size, by Line Of Therapy, 2017-2032 (USD Million)
TABLE 327. Russia Immuno-Oncology Market Size, by End User, 2017-2032 (USD Million)
TABLE 328. Spain Immuno-Oncology Market Size, 2017-2032 (USD Million)
TABLE 329. Spain Immuno-Oncology Market Size, by Therapy Type, 2017-2032 (USD Million)
TABLE 330. Spain Immuno-Oncology Market Size, by Cell Therapy, 2017-2032 (USD Million)
TABLE 331. Spain Immuno-Oncology Market Size, by Checkpoint Inhibitors, 2017-2032 (USD Million)
TABLE 332. Spain Immuno-Oncology Market Size, by Indication, 2017-2032 (USD Million)
TABLE 333. Spain Immuno-Oncology Market Size, by Breast Cancer, 2017-2032 (USD Million)
TABLE 334. Spain Immuno-Oncology Market Size, by Melanoma, 2017-2032 (USD Million)
TABLE 335. Spain Immuno-Oncology Market Size, by Line Of Therapy, 2017-2032 (USD Million)
TABLE 336. Spain Immuno-Oncology Market Size, by End User, 2017-2032 (USD Million)
TABLE 337. Global Immuno-Oncology Market Share, by Key Player, 2025
TABLE 338. Global Immuno-Oncology Market, Key Experts

Companies Mentioned

  • Agenus Inc.
  • Allogene Therapeutics, Inc.
  • Amgen Inc.
  • AstraZeneca PLC
  • Autolus Limited
  • BeiGene, Ltd.
  • BioNTech SE
  • Bristol-Myers Squibb Company
  • Celgene Corporation
  • Eli Lilly and Company
  • Gilead Sciences, Inc.
  • GlaxoSmithKline plc
  • Immutep Ltd.
  • Johnson & Johnson
  • Juno Therapeutics, Inc.
  • Legend Biotech Corporation
  • Merck & Co., Inc.
  • Moderna, Inc.
  • Novartis AG
  • Pfizer Inc.
  • Regeneron Pharmaceuticals, Inc.
  • Roche Holding AG
  • Sanofi S.A.
  • Takeda Pharmaceutical Company Limited

Related Topics

Related Reports

Immuno Oncology Assays Market - Global Forecast 2026-2032 - Product Image

Immuno Oncology Assays Market - Global Forecast 2026-2032

  • Report
  • 185 Pages
  • Global
From
Immuno-oncology Clinical Trials Market - Global Forecast 2026-2032 - Product Image

Immuno-oncology Clinical Trials Market - Global Forecast 2026-2032

  • Report
  • 198 Pages
  • Global
From
Immuno-Oncology - Global Strategic Business Report - Product Image

Immuno-Oncology - Global Strategic Business Report

  • Report
  • 246 Pages
  • Global
From
Immuno-Oncology Drugs Market Outlook 2025-2034: Market Share, and Growth Analysis - Product Image

Immuno-Oncology Drugs Market Outlook 2025-2034: Market Share, and Growth Analysis

  • Report
  • 160 Pages
  • Global
From
Immuno-Oncology Drugs Market Report 2026 - Product Image

Immuno-Oncology Drugs Market Report 2026

  • Report
  • 250 Pages
  • Global
From
Copyright © 2002-2026 Research and Markets. All Rights Reserved.